King Altace Scripts Shift To 10 Mg; Dosage From HOPE Trial Helps Fuel Growth
Executive Summary
Prescriptions for King's ACE inhibitor Altace (ramipril) are shifting to the 10 mg strength, the same dose used in the Heart Outcomes Prevention Evaluation study, CEO Jefferson Gregory said
You may also be interested in...
FDA Hormone Therapy Risk Management Options Include Narrower Indication
FDA is considering limiting hormone therapy indications to patients with more severe menopausal symptoms or those at a high risk for osteoporosis, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said Oct. 24
From The Quarterly Conference Calls
Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...
King Plans $45 Mil. On Altace DTC Campaign; DREAMs Of Diabetes Indication
King and Wyeth-Ayerst expect to spend approximately one-half of the $90 mil. set aside for Altace promotion on direct-to-consumer advertising for the ACE inhibitor.